PERSPECTIVES OF TREATMENT OF TERMINAL LIVER DISEASE IN CHRONIC HCV-INFECTION
Abstract
Aim. Assessment of role of HBV viral proteins in liver disease progression in chronic HCV-infected patients.
Methods. 2934 patients were included into the study, in whom serological markers of HBV- and HCV-infection were evaluated. 80 patients were randomly selected for determination of role of anti-HBcor in progression of HCV-induced chronic liver disease. Role of latent HBV-infection in development of hepato-cellular carcinoma was assessed in 28 liver transplant recipients with chronic HCV-infection.
Results. Serological markers of HBV- and/or HCV-infection were detected in 28%. Presence of anti-HBcor IgG was significantly oftener registered in patients with anti-HCV-antibodies (81 vs 17% in absence of anti-HCV-antibodies, p<0,05). Presense of anti-HBcor antibodies did not influenced significantly the activity of liver damage. In HCV-infected liver transplant recipients HBV DNA in liver tissue could be detected in absence of HBs-antigene. anti-HBcor was associated with trend of increasing of risk of hepato-cellular carcinoma development.
Conclusion. All potential liver donors should be examined for anti-HBV- and anti-HCV-antibodies presence.
About the Authors
E. N. German
ГОУ ВПО «Первый Московский государственный медицинский университет им. И.М. Сеченова Минздравсоцразвития России»
Russian Federation
Russian Federation
М. V. Mayevskaya
ГОУ ВПО «Первый Московский государственный медицинский университет им. ИМ. Сеченова Минздравсоцразвития России»
Russian Federation
Russian Federation
O. I. Andreytseva
НИИ скорой помощи им. Н.В. Склифософского Департамента здравоохранения г. Москвы
Russian Federation
Russian Federation
V. T. Ivashkin
ГОУ ВПО «Первый Московский государственный медицинский университет им. И.М. Сеченова Минздравсоцразвития России»
Russian Federation
Russian Federation
A. V. Chzhao
НИИ скорой помощи им. Н.В. Склифософского Департамента здравоохранения г. Москвы
Russian Federation
Russian Federation
References
1. Абдурахманов Д.Т. Латентная HBV-инфекция в патогенезе хронических заболеваний печени / / Рос. журн. гастроэнтерол., гепатол. и колопроктол. — 2002.-Vol. 6 .- С . 31-37.
2. Андрейцева О.И. Возможности ортотопической трансплантации печени при лечении больных с терминальными поражениями печени // Consilium Medicum. - 2004. - T. 6, № 6. - С. 25-27.
3. Галимова С.Ф., Маевская М.В., Ивашкин В.Т. Современные подходы к лечению больных хроническим гепатитом В / / Рос. журн. гастроэнтерол., гепатол. и колопроктол. — 2009. — № 3. — С. 14—16.
4. Ермолов Е.С., Чжао А.В., Гуляев В.А. и др. Возможности использования инфицированных трупных доноров для выполнения трансплантации печени / / Хирургия. Журнал им. Н.И. Пирогова. — 2006. — № 3. - С. 72.
5. Ивашкин В.Т., Морозова М.А., Маевская М.В. и др. Факторы риска развития гепатоцеллюлярной карциномы / / Рос. журн. гастроэнтерол., гепатол. и колопроктол. — 2009. - № 1. — С. 4—16.
6. Подымова С.Д. Болезни печени: Руководство для врачей. 4-е изд., перераб. и доп. — М.: Медицина, 2005. — С. 23.
7. Boonstra A., Woltman А.М., Janssen H.L. Immunology of hepatitis В and hepatitis C virus infections / / Clin. Gastroenterol. Best Pract. Res. — 2008. — Vol. 22, N 6. — P. 1049-1061.
8. Brechot C. Hadchouel M. Scotto J. et a!. State of hepatitis В virus DNA in hepatocytes of patients with hepatitis В surface antigen-positive and -negative liver diseases // Proc. Natl Acad. Sci. USA. - 1981. - Vol. 78. - P. 3906-3910.
9. Brechot C., Thiers V, Kremsdorf D. et al. Persistent hepatitis B virus infection in subjects without hepatitis B surface antigen: clinically significant or purely «occult»? / / Hepatology (Baltimore). - 2001. - Vol. 34. - P. 194-203.
10. Cacciola /., Pollicino T., Squadrito G., el al. Occult hepatitis B virus infection in patients with chronic hepatitis C liver disease // N. Engl. J. Med. — 1999. — Vol. 341. — P. 22-26.
11. Chemin /., Trepo C. Clinical impact of occult HBV infectio ns//J. Clin. Virol. - 2005. - Vol. 34. - P. 515-521.
12. ChenS.Y., KaoC.F.,ChenC.M.e1al. Mechanisms for inhibition of hepatitis B virus gene expression and replication by hepatitis C virus core protein / / J. Biol. Chem. — 2003. — Vol. 278. - P. 591-607.
13. Chewier M.C., St-Louis M., Perreault J. etal. Detection and characterization of hepatitis B virus of anti-hepatitis B core antigen-reactive blood donors in Quebec with an inhouse nucleic acid testing assay // Transfusion. — 2007. — Vol. 47, N 10.- P . 1794-1802.
14. Fukuda R., Ishimura M., Kushiyama Y. et al. Hepatitis B virus with X gene mutations is associated with the majority of serologically «silent» non-b non-c chronic hepatitis // Microbiol. Immunol. — 1996. — Vol. 40. — P. 481—488.
15. Hu K.Q. Occult hepatitis B virus infection and its clinical implications / / J. Viral Hepat. — 2002. — Vol. 9. — P. 243-257.
16. Koike K., Kobayashi M., Gondo M. et al Hepatitis B virus DNA is frequently found in liver biopsy samples from hepatitis C virus-infected chronic hepatitis patients // J. Med. Virol. - 1998. - Vol. 54. - P. 249-255.
17. Kreutz C. Molecular, immunological and clinical properties of mutated hepatitis B viruses // J. Cell. Mol. Med. — 2002. - Vol. 6. - P. 113-143.
18. Larghi A., Leffler D., Frucht H. et ai Hepatitis B virus reactivation after kidney transplantation and new onset lymphoma //J. Clin. Gastroenterol. — 2003. — Vol. 36. — P. 276-280.
19. Pollicino T., Squadrito G., Cerenzia G. et al. Hepatitis B virus maintains its pro-oncogenic properties in the case of occult HBV infection / / Gastroenterology. — 2004. — Vol. 126. - P. 102-110.
20. Raimondo G. Occult hepatitis B virus infection / / J. Hepatol. - 2007. - Vol. 46. - P. 160-170.
21. Raimondo G., Balsano C., Craxi A. et al. Occult hepatitis B virus infection // Dig. Liver Dis. — 2000. — Vol. 32. — P. 822-826.
22. SaitoH., Masuda T., TadaS.etal. Hepatocellularcarcinoma in Keio affiliated hospitals — diagnosis, treatment, and prognosis of this disease // Keio J Med. — 2009. — Vol. 58, N 3. - P. 161-175.
23. Schuttler C.G., Fiedler N., Schmidt K. et al. Suppression of hepatitis B virus enhancer 1 and 2 by hepatitis C virus core protein / / J. Hepatol. — 2002. — Vol. 37. — P. 855—862.
24. Shih C.M., Lo S.J., Miyamura T. etal. Suppression of hepatitis B virus expression and replication by hepatitis C virus core protein in HuH-7 cells // J. Virol. — 1993. — Vol. 67. — P. 5823-5832.
25. Torbenson M., Thomas D.L. Occult hepatitis B / / Lancet Infect. Dis. - 2002. - Vol. 2. - P. 479-486.
26. Uchida T., Kaneita X, Gotoh K. et al. Hepatitis C virus is frequently coinfected with serum marker-negative hepatitis B virus: probable replication promotion of the former by the latter as demonstrated by in vitro cotransfection // J. Med. Virol. - 1997. - Vol. 52. - P. 399-405.
27. Villa E., Grottola A., Buttafoco P. et al. Evidence for hepatitis B virus infection in patients with chronic hepatitis C with and without serological markers of hepatitis B // Dig. Dis. Sci. - 1995. - Vol. 40. - P. 8-13.
Review
Views:
258
Email this article 